Compare

Theravance Biopharma/$TBPH

1D1W1M3M6MYTD1Y5YMAX

About Theravance Biopharma

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Ticker
$TBPH
Sector
Health
Primary listing
NASDAQ
Employees
90
Headquarters
South San Francisco, United States
Website
www.theravance.com

TBPH Metrics

BasicAdvanced
$884M
16.30
$1.05
0.25
-

What the Analysts think about TBPH

Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Analyst projections of the future price of Theravance Biopharma stock.

Bulls say / Bears say

YUPELRI continued to grow: US sales reached $70.7 million in the second quarter of 2026, up 7% year on year, while hospital-channel doses rose 25%. That provides a growing commercial base for the business. (Theravance Biopharma)
Cost cuts were improving operating leverage: operating expenses, excluding restructuring and transaction costs, fell 35% year on year in Q2. Management expected the restructuring to deliver about $60–70 million in annualised cash flow once fully in place. (Theravance Biopharma)
YUPELRI generic challengers agreed to licensed launch dates in April 2039, subject to specified exceptions. That settlement reduced the near-term threat of generic competition to the product’s sales. (Zymeworks)
Ampreloxetine’s Phase 3 CYPRESS trial missed its primary endpoint, with similar trends in key secondary measures. The FDA said the existing data package would not support approval, leaving any route forward dependent on another pivotal trial. (SEC)
The acquisition by Zymeworks closed on 23 September 2026: ordinary shares were converted into $17 cash per share plus a contingent value right, and Nasdaq trading was suspended. TBPH therefore no longer represents an ongoing listed-equity investment. (SEC)
The business was heavily reliant on YUPELRI: all Q2 revenue came from the Viatris collaboration, while the company reported an $8.3 million operating loss. That concentration left little revenue diversification if YUPELRI’s growth weakened. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

TBPH Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

TBPH Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

TBPH News

AllArticlesVideos

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

MarketBeat1 month ago

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.